In this podcast episode, Jokūbas Leikauskas, Editor, BioInsights, speaks to Trevor Hallam, who served as Chief Scientific Officer of Sail Biomedicines until July 2025. The interview, recorded in June 2025, explores advances in RNA therapeutics, particularly circular RNA (circRNA or eRNA) technologies, and how they may help overcome current limitations in delivery, durability, and specificity for applications such as CAR-T cell therapies and autoimmune disease treatment.
All content for The BioInsights Podcast is the property of BioInsights and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this podcast episode, Jokūbas Leikauskas, Editor, BioInsights, speaks to Trevor Hallam, who served as Chief Scientific Officer of Sail Biomedicines until July 2025. The interview, recorded in June 2025, explores advances in RNA therapeutics, particularly circular RNA (circRNA or eRNA) technologies, and how they may help overcome current limitations in delivery, durability, and specificity for applications such as CAR-T cell therapies and autoimmune disease treatment.
Spatial mapping: shaping the future of I-O diagnostics and treatment
The BioInsights Podcast
38 minutes
11 months ago
Spatial mapping: shaping the future of I-O diagnostics and treatment
Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks with Banafshé Larijani, Director of the Centre for Therapeutic Innovation, University of Bath, about the development and application of a novel spatial mapping technology designed to improve cancer diagnostics and personalize treatment planning.
The BioInsights Podcast
In this podcast episode, Jokūbas Leikauskas, Editor, BioInsights, speaks to Trevor Hallam, who served as Chief Scientific Officer of Sail Biomedicines until July 2025. The interview, recorded in June 2025, explores advances in RNA therapeutics, particularly circular RNA (circRNA or eRNA) technologies, and how they may help overcome current limitations in delivery, durability, and specificity for applications such as CAR-T cell therapies and autoimmune disease treatment.
